Pictured: Eytan Stein
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, December 11, 2014

An experimental drug for blood cancers with certain genetic mutations is showing promise in early-stage trials.

Pictured: Viviane Tabar
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Monday, December 1, 2014

Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture.

Pictured: Jedd Wolchok, Alexandra Snyder Charen and Timothy Chan
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, November 20, 2014

In people with melanoma who respond to the drug ipilimumab, certain mutations make tumors more visible to the immune system.

Michel Sadelain and Prasad Adusumilli
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, November 19, 2014

A study in mouse models suggests how modified T cells may be used to treat tumors in the area just outside the lungs.

(From left) MSK investigators Michael Berger, José Baselga, and Maurizio Scaltriti, and graduate student Pau Castel.
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Monday, November 17, 2014

A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors.

Pictured: William Lee, Chris Sander & Nils Weinhold
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, November 13, 2014

In a study of patient tumor samples, researchers have found common mutations in parts of the genome that control gene regulation.

Gregory Riely
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Wednesday, November 12, 2014

MSK lung cancer patients benefit from a powerful genomic test that looks for mutations in 341 genes to help determine the best treatment.

Pictured: Joao Xavier & Eric Pamer
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Monday, November 10, 2014

Clostridium difficile infections are a growing problem, but MSK researchers are looking for innovative ways to prevent and treat them.

Cancer biologist Andrea Ventura
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, November 6, 2014

For the first time, Memorial Sloan Kettering scientists have created a mouse model that replicates a subtype of non-small cell lung cancer caused by a chromosomal rearrangement — a type of mutation that is common in cancers but thus far has been very difficult to study.

A student asks a question at last year’s "Major Trends” seminar.
Event
By Julie Grisham, MS, Science Writer/Editor  |  Monday, November 3, 2014

Every year, MSK gives high school students and their teachers the opportunity to learn about cutting-edge biomedical research from our scientists.

RISE Program Clinical Director Debra Mangino discusses next steps with a patient.
In the Clinic
By Andrea Peirce, BA, Writer/Editor  |  Friday, October 31, 2014

The team of experts in our RISE Program tailor each woman’s surveillance plan based on the latest findings in breast cancer risk, prevention, and treatment.

Pictured: Jorge Reis-Filho and Britta Weigelt
In the Lab
By Jim Stallard, MA, Writer/Editor  |  Tuesday, October 28, 2014

Genetic alterations linked to a rare salivary cancer could also shed light on more common malignancies.

Pictured: Pseudomonas aeruginosa
In the Lab
By Jim Stallard, MA, Writer/Editor  |  Tuesday, October 21, 2014

MSK researchers discover that the body senses and attacks harmful bacteria indirectly after the pathogens cause stress within the cells.

Q&A
By Esther Napolitano, BS, Science Writer/Editor  |  Monday, October 20, 2014

Medical oncologist Paul Sabbatini demystifies common misconceptions surrounding clinical trials.

DNA wrapped around histones
Decoder
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, October 14, 2014

Physician-scientist Omar Abdel-Wahab explains epigenetics, a growing field based on the study of genetic changes that are not part of the DNA code, and how it relates to cancer.

Center News

Stay Informed

Get the latest information about cancer care and research every month.